Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer
This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.
• Men and women age \>18 yrs
• Biopsy proven NSCLC with brain metastases (treated or untreated)
• Life-expectancy of ≥3 months in the opinion of the treating physician
• Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
• Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan
• Ability to understand and willingness to sign a written informed consent document.
• Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging
• \[18F\]-FDG PET/CT within 21 days of enrollment
• MRI brain within 21 days of enrollment
⁃ Eastern Cooperative Oncology Group Performance Status ≤ 2
⁃ Glomerular filtration rate (GFR) ≥ 60